Adrian Bot
Scientific, Executive Officer, Vice President - Research Development Capstan Therapeutics
Adrian Bot, M.D., Ph.D. is a biopharma executive with three decades of experience in research and development with a focus on immune, cell and gene therapy. Most recently, he was the founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics, a company developing next generation RNA-based precision medicines. Previously, he held leadership roles at Kite Pharma and Kite, a Gilead Company, including Chief Scientific Officer and Vice President of Translational Medicine and Discovery Research, respectively. At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer. Dr. Bot also served in various senior R&D leadership positions at MannKind Corp and Alliance Pharmaceutical Corp, La Jolla, California. He obtained his M.D. in Romania in 1993, his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998 and subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla, California.
Seminars
- What are the driving factors behind recent deals, what are the unique aspects of LNP technology that investors are most focused on?
- What key factors do investors evaluate when assessing the potential and risks of LNP technologies?
- Beyond individual drug candidates, how do investors envision the broader potential and future impact of these LNP partnerships?
- Advancing Chimeric Antigen Receptor T-cell therapies: lessons learned from ex vivo engineered CAR T cell products
- Paving the way to in vivo generation of CAR-expressing immune cells: experience to date including viral and RNA-LNP based approaches
- The future of immunotherapy: bringing together precision medicine and nanotechnologies to advance safe, potent and tunable treatments for a broad range of disease categories
